Virology And Pathogenesis
- DNA virus; member of Hepadnaviridae family.
- Genome contains four open reading frames: S (surface), C (core), X (regulatory), P (polymerase).
- Inherently non-cytopathogenic; hepatocyte injury primarily immune-mediated.
- Cytotoxic T-lymphocytes target viral antigens (HBcAg, HBeAg) expressed on hepatocyte surface, inducing cell lysis.
- Perinatal acquisition typically induces robust immune tolerance, minimizing acute inflammation while permitting high viral replication.
Epidemiology And Transmission
- Perinatal (vertical) transmission constitutes primary pediatric infection route; highest risk if mother HBeAg-positive.
- Horizontal transmission via contaminated blood, sexual contact, institutional care.
- Chronicity risk inversely related to age of acquisition: ~90% in infants, 20-30% in children 1-5 years, <5% in adults.
- Incubation period ranges 45-160 days.
Clinical Manifestations
- Pediatric infections predominately asymptomatic.
- Prodromal phase features serum sickness-like syndrome: arthralgia, macular/urticarial rashes, papular acrodermatitis (Gianotti-Crosti syndrome).
- Acute symptomatic phase: anorexia, nausea, malaise, fatigue, jaundice.
- Extrahepatic manifestations: polyarteritis nodosa, membranous glomerulonephritis, leukocytoclastic vasculitis, Guillain-Barré syndrome, aplastic anemia.
Diagnostic Serology
| Marker Profile | Clinical Interpretation |
|---|---|
| HBsAg(+), Anti-HBc IgM(+), Anti-HBs(-) | Acute infection. |
| HBsAg(+), Anti-HBc IgG(+), Anti-HBs(-) | Chronic infection (persistence >6 months). |
| HBsAg(-), Anti-HBc IgG(+), Anti-HBs(+) | Resolved past infection; immune. |
| HBsAg(-), Anti-HBc(-), Anti-HBs(+) | Immunity secondary to vaccination. |
| HBeAg(+) | Active viral replication; high infectivity. |
Phases Of Chronic Infection
| Phase | Serologic Profile | Clinical Features | Management |
|---|---|---|---|
| Immune Tolerant | HBeAg(+); High HBV DNA (>20,000 IU/mL); Normal ALT. | Minimal hepatic inflammation/fibrosis. Highly infectious. | Monitor regularly. Therapy ineffective/not indicated. |
| Immune Active (Clearance) | HBeAg(+); High HBV DNA (>20,000 IU/mL); Elevated ALT. | Active inflammation. Cytotoxic T-cell activation. Fibrosis progression risk. | Liver biopsy indicated. Antiviral treatment recommended. |
| Inactive Carrier | HBeAg(-); Anti-HBe(+); Low/undetectable DNA (<2000 IU/mL); Normal ALT. | Minimal inflammation. Seroconversion achieved. | Continued monitoring. Risk of hepatocellular carcinoma persists. |
| Reactivation | HBsAg(+); HBeAg(-); Anti-HBe(+); DNA >2000 IU/mL; Elevated ALT. | Precore/core promoter mutants. Active inflammation. | Liver biopsy indicated. Long-term treatment required. |
Management Protocol
General Measures
- Acute infection requires supportive care; monitor synthetic function assessing for acute liver failure.
- Goal of chronic therapy: Suppress viral replication (undetectable DNA), induce HBeAg to anti-HBe seroconversion, prevent cirrhosis and hepatocellular carcinoma.
- Treatment strictly indicated for immune-active phase (persistently elevated ALT, DNA >20,000 IU/mL, active fibrosis).
Pharmacotherapy
| Drug Class | Specific Agents | Clinical Utility And Limitations |
|---|---|---|
| Interferons | Peg-Interferon-alfa | Immunomodulatory. Finite 48-week course. Significant adverse effects (cytopenias, depression). No viral resistance. |
| Nucleoside Analogues | Entecavir | First-line pediatric agent (approved >2 years). Potent viral suppression. High barrier to resistance. |
| Lamivudine | Historically used. Currently discouraged due to high emergence of YMDD mutant resistance (64% at 3 years). | |
| Nucleotide Analogues | Tenofovir disoproxil | First-line agent (approved >12 years). Excellent safety profile. Negligible resistance risk. |
Prevention Strategies
- Universal Vaccination: Recombinant vaccine administered at birth, 1-2 months, and 6 months. Induces protective anti-HBs titers (>10 mIU/mL) in >90-95% of recipients.
- Perinatal Prophylaxis: Hepatitis B immunoglobulin (HBIG) plus Hepatitis B vaccine administered at separate anatomical sites within 12 hours of birth for infants born to HBsAg-positive mothers. Prevents >95% of transmissions.
- Maternal Therapy: Administer antiviral therapy (tenofovir or telbivudine) during third trimester to HBsAg-positive pregnant women demonstrating high viral loads (HBV DNA >200,000 IU/mL) to reduce vertical transmission risk.
Complications
- Liver Cirrhosis: Develops in 3-10% of children with chronic infection.
- Hepatocellular Carcinoma (HCC): Risk elevated 100-fold in chronic carriers; occurs independently of cirrhosis.
- Fulminant Hepatic Failure: High mortality (>30%). Risk significantly amplified by concurrent Hepatitis D virus superinfection or emergence of precore mutant strains. Requires urgent liver transplantation.